BTOG 2022 Summer Meeting | Could ctDNA replace routine tissue testing for genotyping NSCLC?

Sanjay Popat, PhD, MBBS, FRCP, Royal Marsden NHSFT/BTOG Steering Committee, UK, discusses the challenges faced with circulating tumor (ct)DNA implementation and whether it could replace tissue testing as the standard for genotyping non-small cell lung cancer (NSCLC). Currently, the most prominent challenge faced with the implementation of ctDNA for routine genotyping of NSCLC is a lack of funding. Additionally, not every patient sheds ctDNA, resulting in missed tier one drivers. This interview took place at the BTOG 2022 Summer Meeting congress in London.